# EDGAR Filing Document

**Accession Number:** 0001635077
**File Stem:** 0001683168-26-002024
**Filing Date:** 2026-3
**Character Count:** 31085
**Document Hash:** d869ac166fdcf9fbe36f20f1189bf113
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-002024.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001683168-26-002024

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260319

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260319

**DATE AS OF CHANGE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aclarion, Inc.
- **CENTRAL INDEX KEY:** 0001635077
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 473324725
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41358
- **FILM NUMBER:** 26774397

**BUSINESS ADDRESS:**
- **STREET 1:** 8181 ARISTA PLACE
- **STREET 2:** STE 100
- **CITY:** BROOMFIELD
- **STATE:** CO
- **ZIP:** 80021
- **BUSINESS PHONE:** 833 275 2266

**MAIL ADDRESS:**
- **STREET 1:** 8181 ARISTA PLACE
- **STREET 2:** STE 100
- **CITY:** BROOMFIELD
- **STATE:** CO
- **ZIP:** 80021

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nocimed, Inc.
- **DATE OF NAME CHANGE:** 20150226

?xml version='1.0' encoding='ASCII'? Aclarion, Inc. 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 19, 2026**

**Aclarion, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41358** | **47-3324725** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| **8181 Arista Place, Suite 100** |  |
| **Broomfield, Colorado** | **80021** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(833) 275-2266**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | ACON | Nasdaq Stock Market |
| Common Stock Warrants | ACONW | Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

The information set forth in Item 3.03 of this Current Report is incorporated into this Item 1.01 by reference.

**Item 3.03. Material Modification to Rights of Security Holders.**

On March 19, 2026, the board of directors (the "***Board***") of Aclarion, Inc., a Delaware corporation (the "***Company***"), adopted a stockholder rights agreement and declared (i) a dividend of one right (a "***Right***") for each outstanding share of Company common stock, par value $0.00001 per share ("***Common Stock***"), to stockholders of record at the close of business on March 30, 2026 (the "***Record Date***") and (ii) a dividend of the aggregate number of Rights equal to the number of shares of Common Stock acquirable upon complete exercise of each Rights-Eligible Warrant for each Rights-Eligible Warrant (as defined in the Stockholder Rights Agreement) (without regard to any limitations on exercise thereof, including any beneficial ownership limitation contained therein) in each case outstanding at the close of business on the Record Date, including the warrants issued pursuant to that certain Warrant Agent Agreement, dated as of April 21, 2022, by and between the Company and VStock Transfer, LLC, as warrant agent (the "***Public Warrants***").

Each Right entitles its holder, subject to the terms of the Rights Agreement (as defined below), to purchase from the Company one one-thousandth of a share of Series D Junior Participating Preferred Stock, par value $0.00001 per share ("***Preferred Stock***"), of the Company at an exercise price of $14.00 per Right, subject to adjustment. The description and terms of the Rights are set forth in a stockholder rights agreement, dated as of March 19, 2026 (the "***Rights Agreement***"), between the Company and VStock Transfer, LLC, as rights agent (and any successor rights agent, the "***Rights Agent***").

The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in the Company. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to make informed decisions that are in the best interest of Aclarion and its stockholders.

The Rights Plan was not adopted in response to any specific proposal to acquire control of the Company and is not intended to deter offers or preclude the Board from considering offers that are fair and otherwise in the best interests of all the Company's stockholders. The Rights Agreement is not expected to interfere with any merger or business combination approved by the Board.

***The Rights***. The Rights will attach to any shares of Common Stock that become issued and outstanding after the Record Date and prior to the earlier of (i) the Distribution Time (as defined below) and (ii) the Expiration Time (as defined below), and in certain other circumstances described in the Rights Agreement, including shares of Common Stock issued upon the exercise of Rights-Eligible Warrants.

Until the Distribution Time, the Rights are associated with Common Stock and Rights-Eligible Warrants, as applicable, and evidenced by Common Stock certificates or Public Warrants certificates or instruments representing Rights-Eligible Warrants (other than the Public Warrants), or, in the case of uncertificated shares of Common Stock or uncertificated Public Warrants, the book-entry account that evidences record ownership of such shares of Common Stock or Public Warrants, which will contain a notation incorporating the Rights Agreement by reference. Until the Distribution Time, the Rights are transferable with, and only with, the underlying shares of Common Stock or Rights-Eligible Warrants, as applicable.

Until the Distribution Time, the surrender for transfer of any shares of Common Stock or any Rights-Eligible Warrants will also constitute the transfer of the Rights associated with those shares or warrants, and the exercise of any Rights-Eligible Warrants will result in the cancellation and retirement of the associated Rights. As soon as practicable after the Distribution Time, separate rights certificates will be mailed to holders of record of Common Stock or Rights-Eligible Warrants as of the Distribution Time. From and after the Distribution Time, the Rights will be represented solely by the separate rights certificates.

The Rights are not exercisable until the Distribution Time. Until a Right is exercised, its holder will have no rights as a stockholder of the Company, including the right to vote or to receive dividends.

***Separation and Distribution of Rights; Exercisability***. Subject to certain exceptions, the Rights become exercisable and trade separately from Common Stock or Rights-Eligible Warrants only upon the "***Distribution Time***," which occurs upon the earlier of:

&nbsp;&nbsp;&nbsp;&nbsp;· the close of business on the tenth (10th) day after the "  ***Stock Acquisition Date***" (which is defined as (a)
the first date of public announcement that any person or group has become an Acquiring Person or (b) such other date, as determined by
the Board, on which a person or group has become an Acquiring Person); and

&nbsp;&nbsp;&nbsp;&nbsp;· the close of business on the tenth (10th) business day (or such later date as may be determined by the Board prior to such time as
any person or group becomes an Acquiring Person) after the commencement of a tender offer or exchange offer that, if consummated, would
result in a person or group becoming an Acquiring Person, unless such tender or exchange offer is conditioned on the redemption of the
Rights or termination of the Rights Agreement.

"***Acquiring Person***" means a person or group that, together with its affiliates and associates, beneficially owns 10% or more of the outstanding shares of Common Stock (with certain exceptions, including those described below).

An Acquiring Person does not include:

&nbsp;&nbsp;&nbsp;&nbsp;· the Company or any subsidiary of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;· any officer, director or employee of the Company or any subsidiary of the Company in his or her capacity as such;

&nbsp;&nbsp;&nbsp;&nbsp;· any employee benefit plan of the Company or of any subsidiary of the Company or any entity or trustee holding (or acting in a fiduciary
capacity in respect of) shares of capital stock of the Company for or pursuant to the terms of any such plan or for the purpose of funding
other employee benefits for employees of the Company or any subsidiary of the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;· any person or group that, together with its affiliates and associates, as of immediately prior to the first public announcement of
the adoption of the Rights Agreement, beneficially owns 10% or more of the outstanding shares of Common Stock, so long as such person
or group continues to beneficially own at least 10% of the outstanding shares of Common Stock and does not acquire shares of Common Stock
to beneficially own an amount equal to or greater than the greater of (a) 10% and (b) the sum of the lowest beneficial ownership of such
person or group since the public announcement of the adoption of the Rights Agreement plus one share of Common Stock.

In addition, the Rights Agreement provides that no person or group will become an Acquiring Person as a result of security purchases or issuances directly from the Company or through an underwritten offering approved by the Board. Also, a person or group will not be an Acquiring Person if the Board determines that such person or group has become an Acquiring Person inadvertently and such person or group has already divested or divests as promptly as practicable a sufficient number of shares so that such person or group would no longer be an Acquiring Person.

Any existing stockholder or stockholder group that beneficially owns 10% or more of Common Stock shall be grandfathered at its current ownership level, but the Rights held by them will not be exercisable if, at any time after the announcement of the Rights Agreement, such stockholder or stockholder group increases its ownership of Common Stock.

***Expiration Time***. The Rights will expire on the earliest to occur of (i) the close of business on March 18, 2027 (the "***Final Expiration Time***"), (ii) the time at which the Rights are redeemed by the Company (as described below), (iii) the time at which the Rights are exchanged by the Company (as described below), and (iv) the closing of any merger or other acquisition transaction involving the Company pursuant to a merger or other acquisition agreement that has been approved by the Board before any person or group becomes an Acquiring Person (the earliest of clauses (i), (ii), (iii) and (iv) being herein referred to as the "***Expiration Time***").

***Flip-in Event***. In the event that any person or group (other than certain exempt persons) becomes an Acquiring Person (a "***Flip-in Event***"), each holder of a Right (other than such Acquiring Person, any of its affiliates or associates or certain transferees of such Acquiring Person or of any such affiliate or associate, whose Rights automatically become null and void) will have the right to receive, upon exercise, Common Stock having a value equal to two (2) times the exercise price of the Right.

***Flip-over Event***. In the event that, at any time following the Stock Acquisition Date, any of the following occurs (each, a "***Flip-over Event***"):

&nbsp;&nbsp;&nbsp;&nbsp;· the Company consolidates with, or merges with and into, any other entity, and the Company is not the continuing or surviving entity;

&nbsp;&nbsp;&nbsp;&nbsp;· any entity engages in a share exchange with or consolidates with, or merges with or into, the Company, and the Company is the continuing
or surviving entity and, in connection with such share exchange, consolidation or merger, all or part of the outstanding shares of Common
Stock are changed into or exchanged for stock or other securities of any other entity or cash or any other property; or

&nbsp;&nbsp;&nbsp;&nbsp;· the Company sells or otherwise transfers, in one transaction or a series of related transactions, 50% or more of the Company's
assets, cash flow or earning power,

each holder of a Right (except Rights that previously have been voided as described above) will have the right to receive, upon exercise, common stock of the acquiring company having a value equal to two (2) times the exercise price of the Right.

***Preferred Stock Provisions****.* Each share of Preferred Stock, if issued:

&nbsp;&nbsp;&nbsp;&nbsp;· will not be redeemable;

&nbsp;&nbsp;&nbsp;&nbsp;· will entitle the holder thereof, when, as and if declared, to quarterly dividend payments equal to the greater of $1,000 per share
and 1,000 times the amount of all cash dividends plus 1,000 times the amount of non-cash dividends or other distributions paid on one
share of Common Stock;

&nbsp;&nbsp;&nbsp;&nbsp;· will entitle the holder thereof to receive $1,000 plus accrued and unpaid dividends per share upon liquidation;

&nbsp;&nbsp;&nbsp;&nbsp;· will have the same voting power as 1,000 shares of Common Stock; and

&nbsp;&nbsp;&nbsp;&nbsp;· if shares of Common Stock are exchanged by means of a merger, consolidation or a similar transaction, will entitle the holder thereof
to a per share payment equal to the payment made on 1,000 shares of Common Stock.

***Anti-dilution Adjustments***. The exercise price payable-and the number of shares of Preferred Stock or other securities or property issuable-upon exercise of the Rights are subject to adjustment from time to time to prevent dilution:

&nbsp;&nbsp;&nbsp;&nbsp;· in the event of a stock dividend on, or a subdivision, combination or reclassification of, the Preferred Stock;

&nbsp;&nbsp;&nbsp;&nbsp;· if holders of the Preferred Stock are granted certain rights, options or warrants to subscribe for Preferred Stock or convertible
securities at less than the current market price of the Preferred Stock; or

&nbsp;&nbsp;&nbsp;&nbsp;· upon the distribution to holders of the Preferred Stock of evidences of indebtedness or assets (excluding regular quarterly cash dividends)
or of subscription rights or warrants (other than those referred to above).

With certain exceptions, no adjustment in the exercise price will be required until cumulative adjustments amount to at least 1% of the exercise price. No fractional shares of Preferred Stock will be issued and, in lieu thereof, an adjustment in cash will be made based on the market price of the Preferred Stock on the last trading day prior to the date of exercise.

***Redemption; Exchange***. The Board may, at its option, at any time prior to the earlier of (i) the Close of Business on the tenth (10th) day following the Stock Acquisition Date (or if the Stock Acquisition Date shall have occurred prior to the Record Date, the Close of Business on the tenth (10th) day following the Record Date) and (ii) the Final Expiration Time, direct the Company to redeem the Rights in whole, but not in part, at a price of $0.001 per Right (subject to adjustment and payable in cash, Common Stock or other consideration deemed appropriate by the Board). Immediately upon the action of the Board authorizing any redemption, or at a later time as the Board may establish for the effectiveness of the redemption, the Rights will terminate and the only right of the holders of Rights will be to receive the redemption price.

At any time after any person or group becomes an Acquiring Person but before any Acquiring Person, together with all of its affiliates and associates, becomes the beneficial owner of 50% or more of the outstanding shares of Common Stock, the Company may exchange the Rights (other than Rights owned by the Acquiring Person, any of its affiliates or associates or certain transferees of the Acquiring Person or of any such affiliate or associate, whose Rights will have become null and void), in whole or in part, at an exchange ratio of one share of Common Stock, or one one-thousandth of a share of Preferred Stock (or of a share of a class or series of the Company's preferred stock having equivalent rights, preferences and privileges), per Right (subject to adjustment).

***Amendment of the Rights Agreement***. The Company and the Rights Agent may from time to time amend or supplement the Rights Agreement without the consent of the holders of the Rights. However, on or after the Stock Acquisition Date, no amendment can materially adversely affect the interests of the holders of the Rights (other than the Acquiring Person, any of its affiliates or associates or certain transferees of the Acquiring Person or of any such affiliate or associate).

***Miscellaneous***. While the distribution of the Rights will not be taxable to stockholders or to the Company, stockholders may, depending upon the circumstances, recognize taxable income in the event that the Rights become exercisable for Common Stock (or other consideration) or for common stock of the acquiring company or in the event of the redemption of the Rights as described above.

The foregoing description of the Rights Agreement and the Rights does not purport to be complete and is qualified in its entirety by reference to the Rights Agreement, which is filed as Exhibit 4.1 to this Current Report and is incorporated herein by reference.

**Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On the Effective Date, in connection with the adoption of the Rights Agreement described in Item 3.03 of this Current Report, the Board approved a Certificate of Designation of Series D Junior Participating Preferred Stock (the "***Certificate of Designation***"), which designates the rights, preferences and privileges of 10,000 shares of a series of the Company's preferred stock, par value $0.00001 per share, designated as Series D Junior Participating Preferred Stock. The information set forth in Item 3.03 of this Current Report is incorporated into this Item 5.03 by reference.

The Certificate of Designation has been filed with the Delaware Secretary of State and became effective on March 19, 2026. A copy of the Certificate of Designation has been filed as Exhibit 3.1 to this Current Report and is incorporated herein by reference.

The foregoing summary of the Certificate of Designation does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report and incorporated herein by reference.

**Item 8.01. Other Events.**

On March 19, 2026, the Company issued a press release announcing the adoption of the Rights Agreement, among other things. A copy of that press release is filed as Exhibit 99.1 to this Current Report and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

*(d) Exhibits.*

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 3.1 | [Certificate of Designation of Series D Junior Participating Preferred Stock of Aclarion, Inc., dated March 19, 2026](https://www.sec.gov/Archives/edgar/data/1635077/000168316826002019/aclarion_ex0301.htm) (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form 8-A, filed by Aclarion, Inc. with the U.S. Securities and Exchange Commission on March 19, 2026, File No. 001-41358) |
| 4.1 | [Stockholder Rights Agreement, dated as of March 19, 2026, by and between Aclarion, Inc. and VStock Transfer, LLC, as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto)](https://www.sec.gov/Archives/edgar/data/1635077/000168316826002019/aclarion_ex0401.htm) (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form 8-A, filed by Aclarion, Inc. with the U.S. Securities and Exchange Commission on March 19, 2026, File No. 001-41358) |
| 99.1 | [Press Release issued by Aclarion, Inc. on March 19, 2026](aclarion_ex9901.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ACLARION, INC.** | **ACLARION, INC.** |
| March 19, 2026 | By: | /s/ Gregory A. Gould |
|  | Name: | Gregory A. Gould |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](image_001.jpg)

**Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan** 

BROOMFIELD, Colo., March 19, 2026 – Aclarion, Inc. (Nasdaq: ACON, ACONW) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year.

The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to make informed decisions that are in the best interest of Aclarion and its stockholders.

The Rights Plan applies equally to all current and future stockholders. The Rights Plan was not adopted in response to any specific proposal to acquire control of the Company and is not intended to deter offers or preclude the Board from considering offers that are fair and otherwise in the best interests of all the Company's stockholders.

**About the Rights Plan**

The terms of the Rights Plan are similar to those of plans adopted by other publicly traded companies. Pursuant to the Rights Plan, Aclarion declared a dividend distribution of one preferred stock purchase right for (i) each share of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and (ii) each Rights-Eligible Warrant (as defined in the Rights Plan) (without regard to any limitations on exercise thereof), in each case outstanding as of the close of business on March 30, 2026 (the "Record Date"), and further authorized the issuance of one Right for each share of Common Stock and each Rights-Eligible Warrant, in each case, that shall become issued and outstanding between the Record Date and the earlier of the Distribution Time and the Expiration Time (each as defined in the Rights Plan).

One right will automatically attach to each share of Common Stock and each Rights-Eligible Warrant, including shares of Common Stock and additional Rights-Eligible Warrants, if any, that become issued and outstanding after the Record Date and before the rights become exercisable. Initially, these rights will not be exercisable and will trade with, and be represented by, the Common Stock and the Rights-Eligible Warrants, as applicable.

Each right entitles the registered holder thereof to purchase from the Company one one-thousandth (1/1,000th) of a share of Series D Junior Participating Preferred Stock, par value $0.00001 per share, of the Company (the "Preferred Stock") at a cash exercise price of $14.00 per right, subject to adjustment, under certain conditions specified in the Rights Plan.

Under the Rights Plan, the rights will become exercisable if an entity, person or group (the "acquiring person") acquires beneficial ownership of 10% or more of the shares of Common Stock in a transaction not approved by the Board. If a person or group beneficially owns 10% or more of the outstanding shares of Common Stock prior to the Company's announcement of the adoption of the Rights Plan, then that person's or group's existing ownership will be grandfathered and the rights will become exercisable if at any time after the announcement of the adoption of the Rights Plan such person or group increases its ownership of Common Stock. For purposes of the Rights Plan, a person or group beneficially owns, among other things, all shares of Common Stock that such person or group has the right or obligation to acquire, including all shares underlying warrants without regard to any limitations on exercise thereof, including any beneficial ownership limitation contained therein.

In the event that the rights become exercisable due to the triggering ownership threshold being crossed, each right will entitle its holder (other than the person, entity or group triggering the Rights Plan, whose rights will become void and will not be exercisable) to receive shares of Common Stock having a market value equal to two times the exercise price of the right. In addition, in the event of a merger or similar change of control of the Company, each right will entitle its holder (other than the person, entity or group triggering the Rights Plan, whose rights will become void and will not be exercisable) to receive shares of common stock of the acquiring company having a market value equal to two times the exercise price of the right. The Board, at its option, may exchange each right (other than rights owned by the acquiring person that have become void) in whole or in part, at an exchange ratio of one share of Common Stock per outstanding right, subject to adjustment. Except as provided in the Rights Plan, the Board is entitled to redeem the rights, at $0.001 per right.

Under the Rights Plan, any person, entity or group that currently owns more than the triggering percentage prior to the Company's announcement of its adoption of the Rights Plan may continue to own its shares of Common Stock without being deemed an acquiring person but may not acquire any additional shares of Common Stock, or form a group with another owner of Common Stock, without triggering the Rights Plan. The Rights Plan does not contain any dead-hand, slow-hand, no-hand or similar feature that would limit the ability of a future Board to redeem the rights.

The Rights Plan will expire on March 18, 2027, unless earlier redeemed or exchanged by the Board or terminated upon the closing of any merger or other acquisition transaction involving the Company pursuant to an agreement approved by the Board prior to any person becoming an acquiring person.

Additional information regarding the Rights Plan and a copy of the plan will be contained in a current report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

Goodwin Procter LLP is serving as legal counsel for Aclarion.

**About Aclarion, Inc.**

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. For more information, please visit www.aclarion.com.

**Forward-Looking Statements** 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements include, without limitation, implied and express statements relating to the anticipated benefits and expected consequences of the rights plan that Aclarion has adopted. Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. Any express or implied forward-looking statements included in this press release are based on current expectations, are only predictions and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those indicated, including, without limitation, the effectiveness of the rights plan in providing the Board of Directors with time to make informed decisions that are in the best long-term interests of Aclarion and its stockholders. These and other factors that could affect actual results are discussed more fully in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made with the U.S. Securities and Exchange Commission from time to time. Any forward-looking statements contained in this press release represent Aclarion's views only as of today and should not be relied upon as representing its views as of any subsequent date. Aclarion explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

---

| | |
|:---|:---|
| Investor Contacts: | Media Contact: |
| Kirin M. Smith<br>| Jessica Starman<br>|
| PCG Advisory, Inc. | media@aclarion.com |
| ksmith@pcgadvisory.com |  |

---